Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promotion of cardiovascular risk evaluation and preventive multifactorial strategy in metabolic syndrome (SCORE ≤ 5%)
2004-000829-30Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of valsartan and fluvastatin in cardiometabolic risk (CMR) and cardiac morbidity, sponsored by Novartis. Primary endpoint: Change in global cardiovascular risk (SCORE algorithm). Started Jul 2005; status: completed.
02
Drugs
valsartanfluvastatin
03
Conditions
cardiometabolic risk (CMR)cardiac morbidity
Beyond the preview
Go deeper on 2004-000829-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000829-30.